Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination

Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine

(2016) Innocent N. Mbawuike et al.   VACCINE

Natural T Cell–mediated Protection against Seasonal and Pandemic Influenza. Results of the Flu Watch Cohort Study

(2015) Andrew C. Hayward et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine

(2015) Patricia L. Winokur et al.   JOURNAL OF INFECTIOUS DISEASES

Immunomodulatory properties of the vaccine adjuvant alum

(2014) Ewa Oleszycka et al.   CURRENT OPINION IN IMMUNOLOGY

Vaccines for the 21st century

(2014) I. Delany et al.   EMBO Molecular Medicine

Physicochemical and functional characterization of vaccine antigens and adjuvants

(2014) Antu K Dey et al.   Expert Review of Vaccines

Broadly neutralizing antibodies against influenza viruses

(2013) Nick S. Laursen et al.   ANTIVIRAL RESEARCH

Virus infection, antiviral immunity, and autoimmunity

(2013) Daniel R. Getts et al.   IMMUNOLOGICAL REVIEWS

Chimeric Hemagglutinin Influenza Virus Vaccine Constructs Elicit Broadly Protective Stalk-Specific Antibodies

(2013) F. Krammer et al.   JOURNAL OF VIROLOGY

Cellular immune correlates of protection against symptomatic pandemic influenza

(2013) Saranya Sridhar et al.   NATURE MEDICINE

Direct Comparison of an Inactivated Subvirion Influenza A Virus Subtype H5N1 Vaccine Administered by the Intradermal and Intramuscular Routes

(2012) S. M. Patel et al.   JOURNAL OF INFECTIOUS DISEASES

Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans

(2012) Tom M Wilkinson et al.   NATURE MEDICINE

Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses

(2012) N. Pica et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Trends in vaccine adjuvants

(2011) Virgil EJC Schijns et al.   Expert Review of Vaccines

Live and Inactivated Influenza Vaccines Induce Similar Humoral Responses, but Only Live Vaccines Induce Diverse T-Cell Responses in Young Children

(2011) Daniel F. Hoft et al.   JOURNAL OF INFECTIOUS DISEASES

Pandemic 2009 H1N1 vaccine protects against 1918 Spanish influenza virus

(2010) Rafael A. Medina et al.   Nature Communications

Immune surveillance and immunotherapy: Lessons from carbohydrate mimotopes

(2009) Anastas Pashov et al.   VACCINE

Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults

(2009) Wendy A. Keitel et al.   VACCINE

Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults

(2009) Rebecca C. Brady et al.   VACCINE

A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route

(2009) Shital M. Patel et al.   VACCINE

Safety and Immunogenicity of an Inactivated Influenza A/H5N1 Vaccine Given with or without Aluminum Hydroxide to Healthy Adults: Results of a Phase I–II Randomized Clinical Trial

(2008) Wendy A. Keitel et al.   JOURNAL OF INFECTIOUS DISEASES

Effects of Adjuvants on the Safety and Immunogenicity of an Avian Influenza H5N1 Vaccine in Adults

(2008) David I. Bernstein et al.   JOURNAL OF INFECTIOUS DISEASES

Evaluation of the Safety and Immunogenicity of a Booster (Third) Dose of Inactivated Subvirion H5N1 Influenza Vaccine in Humans

(2008) Kenneth M. Zangwill et al.   JOURNAL OF INFECTIOUS DISEASES